在肌缩侧面硬化症和亨廷顿病中使用反感性寡核酸药物
Kaili Ou1, Qingqing Jia1, Dandan Li1
1State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, 510632, China.
Translational neurodegeneration
|January 22, 2025
概括
反感性寡核酸 (ASO) 药物显示出治疗神经退行性疾病的前景,如肌缩侧面硬化症 (ALS) 和亨廷顿病 (HD). 虽然目前的治疗方法可以控制症状,但ASO疗法提供了针对性基因方法,用于潜在的疾病修饰.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肌缩侧面硬化症 (ALS) 和亨廷顿病 (HD) 是复杂的神经退行性疾病,其原因多种多样,包括遗传和环境因素.
- 目前针对ALS和HD的治疗方法提供了症状缓解,但缺乏确定的治疗方法,这凸显了对新型治疗策略的需求.
- 基因疗法是神经退行性疾病中神经保护和疾病纠正的一个有希望的途径.
研究的目的:
- 提供对抗神经退行性疾病的反感性寡核酸 (ASO) 药物开发的全面审查.
- 专注于使用ASO药物治疗肌缩侧面硬化症 (ALS) 和亨廷顿病 (HD) 的治疗策略.
- 探索基于ASO的疗法的作用机制,局限性和临床应用.
主要方法:
- 对ALS和HD的ASO药物临床前和临床研究的文献综述.
- 对ASO干预的遗传点和分子机制的分析.
- 来自动物模型和人类临床试验的疗效和安全数据的评估.
主要成果:
- 针对ALS和HD病理基因的ASO药物在众多动物研究中显示出显著的前景.
- 涉及ASO治疗这些疾病的几项临床试验取得了令人鼓舞的结果.
- ASO药物代表了一种可行的基于基因的治疗方法,用于管理神经退行性疾病.
结论:
- 反感性寡核酸 (ASO) 药物正在成为ALS和HD等神经退行性疾病的强大治疗工具.
- 这些基因向疗法提供了一种潜在的途径,可以改变症状管理之外的疾病进展.
- 进一步的临床开发和ASO药物的应用对于促进ALS和HD患者的治疗选择至关重要.
相关概念视频
siRNA - Small Interfering RNAs
16.5K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.5K
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
Parkinson's Disease: Treatment
198
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
198
Parkinson's Disease: Overview
452
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
452
RNA Interference
25.9K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
25.9K


